Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Trichuris Suis Ova in Autism Spectrum Disorders (TSO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01040221
Recruitment Status : Completed
First Posted : December 29, 2009
Last Update Posted : April 3, 2018
Simons Foundation
Information provided by (Responsible Party):
Eric Hollander, Montefiore Medical Center

Brief Summary:
The purpose of this study is to determine whether Trichuris Suis Ova (TSO) is safe and effective in treating adults with autism spectrum disorder

Condition or disease Intervention/treatment Phase
Autism Drug: Trichuris Suis Ova Phase 1

Detailed Description:

Autism is a pervasive developmental disorder affecting social, communicative, and compulsive/repetitive behaviors. It is also frequently accompanied by aggression, self-injury, and irritability, making care for these individuals a significant challenge for families or institutional settings. Currently risperidone is the only medication approved by the Food and Drug Administration (FDA) for irritability associated with autism, although not all patients respond to risperidone or are able to tolerate its side effects. As such, additional targeted treatments need to be explored in autism. Neuroimmune disturbance has been demonstrated in patients with autism (Ashwood et al., 2006; DelGuidice, 2003) and the presence of neuroinflammation may play a role in initiating or maintaining CNS dysfunction characteristic of the disorder (Pardo et al, 2005). Therefore, there is considerable interest in using immunomodulatory medications to address core and associated symptoms.

Trichuris suis ova (TSO) are the eggs of intestinal helminthes which induce Th2 cytokine release and nonspecifically downregulate Th1 responsiveness (Summers et al., 2003). Treatment with TSO has been shown to have a beneficial effect in autoimmune inflammatory bowel disease (Summers et al, 2003; Summers et al., 2005a; Summers et al., 2005b) and anecdotal reports from patients with autism have demonstrated that TSO may be effective in reducing repetitive behaviors, aggression, self-injury, and impulsivity.

To date, many medications have been used in individuals with autism and the history of psychopharmacology of autism is notable for the exaggerated benefit of a variety of treatments. To date, most medication studies in the field have been open-label without use of a placebo control and without systematic behavioral assessments. The current practice of prescribing medications to patients with autism without scientifically demonstrated efficacy underscores the necessity for methodologically rigorous studies to be conducted.

We propose a double blind placebo-controlled crossover trial of TSO, where subjects would be randomized to receive placebo or TSO for 12 weeks, with a 4 week washout and then 12 weeks of the the treatment not yet received. To assess the effect on social cognition, repetitive behaviors, aggression and irritability, and global functioning in adults with autism spectrum disorder. The objectives of the proposed study are to develop an innovative treatment approach to autism by 1) assessing the safety and efficacy of TSO treatment using behavioral and laboratory outcome measures; 2) determining whether this treatment has sufficient promise to warrant consideration of a larger, multi-centered, placebo-controlled clinical trial; 3) conducting secondary analyses to explore the relationship between clinical features, immune mechanisms, and treatment response.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Trichuris Suis Ova in Autism Spectrum Disorders
Study Start Date : November 2012
Actual Primary Completion Date : June 2014
Actual Study Completion Date : July 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Trichuris Suis Ova (TSO)
the eggs of intestinal helminthes (trichuris suis ova) administered as 2500 ova doses every two weeks.
Drug: Trichuris Suis Ova
TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.

Placebo Comparator: Placebo
placebo dosage received every two weeks.
Drug: Trichuris Suis Ova
TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.

Primary Outcome Measures :
  1. Yale-Brown Obsessive Compulsive Scale (YBOCS): to measure repetitive behaviors [ Time Frame: baseline, 2, 4, 6, 8, 10, 12, 14, 16 weeks ]
  2. Aberrant Behavior Checklist (ABC): to measure aggression and irritability [ Time Frame: baseline, 2, 4, 6, 8, 10, 12, 14, 16 weeks ]
  3. Clinical Global Impression - Improvement (CGI-I): to measure global functioning [ Time Frame: baseline, 2, 4, 6, 8, 10, 12, 14, 16 weeks ]

Secondary Outcome Measures :
  1. Repetitive Behavior Scale-Revised. [ Time Frame: baseline, 2, 4, 6, 8, 10, 12, 14, 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18-35, inclusive, at the time of consent
  2. Outpatient
  3. Meet criteria for the diagnosis of Autism Spectrum Disorder according to the DSM-IV-TR, and supported by the ADOS or ADI-R.
  4. Have an IQ of 70 or greater
  5. Participants who are taking other medications prior to enrollment must be on a stable dose of concomitant medication, including psychotropic, anticonvulsant, or sleep aid for at least 3 months prior to baseline ratings
  6. Be judged reliable for medication compliance and agree to keep appointments for study contacts and tests as outlined in the protocol (both subjects and guardians)
  7. Have a personal or family history of allergies.

Exclusion Criteria:

  1. History of Bipolar disorder or Psychotic Disorders (e.g. schizophrenia or schizoaffective disorders).
  2. Previous diagnosis of Rett's Disorder or Childhood Disintegrative Disorder
  3. Uncontrolled seizure disorders (seizures within the past 6 months)
  4. Pregnant or breast feeding at screening, or at any time during the study
  5. Chronic medical illness that would interfere with or contraindicate participation in the study, or clinically significant abnormalities in baseline laboratory testing or physical exam.
  6. Treatment in the last 12 weeks with cyclosporine, methotrexate, infliximab or immunomodulatory agents
  7. Treatment in the last 2 weeks with antibiotics, antifungal or antiparasitic medications
  8. Presence of any organic or systemic disease or need for a therapeutic intervention, which would confound the interpretation of results.
  9. History of previous treatment with Trichuris Suis Ova (TSO).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01040221

Layout table for location information
United States, New York
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx, New York, United States, 10467
Sponsors and Collaborators
Montefiore Medical Center
Simons Foundation
Layout table for investigator information
Principal Investigator: Eric Hollander, MD Montefiore Medical Center/Albert Einstein College of Medicine
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Eric Hollander, Clinical Professor, Montefiore Medical Center Identifier: NCT01040221    
Other Study ID Numbers: 11-11-384
First Posted: December 29, 2009    Key Record Dates
Last Update Posted: April 3, 2018
Last Verified: March 2018
Keywords provided by Eric Hollander, Montefiore Medical Center:
Autism, Autism Spectrum Disorder
Trichuris Suis Ova
Clinical Trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders